Research Signal – Source date 2021-02-16
A treatment can keep a cancer from worsening for a time without making a tumour measurably shrink. That gap matters in adenoid cystic carcinoma (ACC), a cancer whose course the 2021 review describes as marked by recurrence near its original site and spread to distant parts of the body. Across the treatments it surveys, stable disease predominates, while objective responses and progression-free survival are limited.
The review is not a new treatment experiment, and its abstract does not give comparable response rates for individual therapies. Its central clinical tension is still clear: disease control has been difficult to translate into a stronger response, even as recurrence and metastasis remain defining problems. Understanding the proposed barriers helps explain why the authors point toward new ways to make treatment targets more useful.
Stable disease leaves a difficult clinical problem
“Stable disease” means that a cancer is not shown to have clearly grown or shrunk over the relevant assessment. It can represent a period of control, but it is different from an objective response, in which tumours measurably decrease. The review characterizes the results of the targeted therapies it discusses as largely stopping at stability, alongside limited progression-free survival—the time before disease worsens.
That pattern does not make stability meaningless. It does show why it may be insufficient for ACC: the review presents local recurrence and distant metastasis as persistent features of the disease’s course. The abstract offers no treatment-by-treatment estimates, so it cannot show which approach performs best or how much benefit any one therapy provides. Instead, it frames a broad challenge: whether future approaches can produce stronger responses or longer disease control in a cancer prone to return and spread.
Why checkpoint therapy may struggle
Immune checkpoint inhibitors are designed to help immune cells recognize and attack cancer. The review says ACC is resistant to this approach because of low tumour immunogenicity and a lack of PD-L1 expression. Immunogenicity is how readily a tumour attracts or activates an immune response. PD-L1 is a molecule involved in a signal that can restrain immune attack; its absence, as described in the review, points to a different immune setting from one in which blocking that signal is an obvious route to stronger activity.
Together, these features offer the authors’ explanation for why checkpoint inhibition may have limited effect in ACC. They do not establish that every tumour has identical immune characteristics or that an individual patient can never benefit. The point is that a treatment designed to release a particular immune brake may be poorly matched when the cancer presents little immune visibility and lacks the named target signal.
A different question for proposed targets
The review also raises prostate-specific membrane antigen (PSMA) as a potential target and discusses manipulating target receptors in clinical settings. These proposals shift attention toward the molecules a treatment might recognize: can a useful target be identified or made more usable so that an antibody-based treatment can engage the cancer more effectively?
That is a research direction, not a demonstrated clinical result. The abstract does not describe validation details or show that PSMA targeting or receptor manipulation improves outcomes. Nor does it provide estimates that would allow these ideas to be ranked against the other therapies reviewed. Their significance at this stage is the question they open: whether changing how a target is presented or used could help overcome the limits of approaches that have mostly achieved stability.
What could improve treatment for recurring ACC
For people whose ACC returns locally or spreads, treatments that produce more measurable responses or longer disease control could offer an advance over the limited results described in the review. The proposed PSMA and receptor-directed approaches could contribute if clinical studies show that they improve either outcome. Until then, they are research proposals rather than established options, and any patient benefit remains unproven.
Key Sources
- Primary source: Adenoid cystic carcinoma: a review of clinical features, treatment targets and advances in improving the immune response to monoclonal antibody therapy.
DOI or Journal Page · Review or Meta-Analysis · 2021-02-16
Keep exploring